Author

T. Melkadze

Observed name: T Melkadze

Observed institution: Georgian National Museum

OpenAlex ID: A5026016306

114M0 First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3

2023 · E. Kalinka, I. Bondarenko, et al. · Journal of Thoracic Oncology · 6

PDF

LBA9 Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005)

2022 · Y. Cheng, L. Han, et al. · Annals of Oncology · 6

2MO Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2- metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial

2024 · M. Oliveira, E.P. Hamilton, et al. · ESMO Open · 3

PDF

MA10.09 Cemiplimab Plus Chemotherapy vs Chemotherapy in Advanced NSCLC: 5-Year Results from Phase3 EMPOWER-Lung 3 Part 2 Trial

2025 · A. Baramidze, T. Makharadze, et al. · Journal of Thoracic Oncology · 2

122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I

2022 · A. Baramidze, M. Gogishvili, et al. · Immuno-Oncology Technology · 2

244MO AdvanTIG-302: Phase III study of ociperlimab (OCI) + tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death-ligand 1 (PD-L1) high, untreated, locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)

2025 · M. Reck, M. Socinski, et al. · Immuno-Oncology Technology · 1

144P First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1

2024 · T. Makharadze, M. Gogishvili, et al. · Immuno-Oncology Technology · 1

PDF

1438P Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3

2023 · T. Makharadze, M. Gogishvili, et al. · Annals of Oncology · 1

PDF

50 Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: Longer follow-up results from the phase III EMPOWER-Lung 3 trial

2023 · T. Makharadze, M. Gogishvili, et al. · Journal of Thoracic Oncology · 1

PDF

318P EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

2022 · M. Gogishvili, T. Melkadze, et al. · Annals of Oncology · 1

P3.317: First-Line Maintenance With Serplulimab for Extensive-Stage Small Cell Lung Cancer: A Post-Hoc Analysis and Meta-Analysis

2026 · H. Liu, L. Han, et al. · Journal of Thoracic Oncology

493O STAR-221: A phase III study of first-line (1L) domvanalimab (D), zimberelimab (Z), and chemotherapy (chemo) vs nivolumab (N) + chemo in advanced HER2-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC)

2026 · Y.Y. Janjigian, S.Y. Rha, et al. · Annals of Oncology

PDF

78P Patient-reported outcomes (PROs) of cemiplimab plus chemotherapy in advanced non-small cell lung cancer (aNSCLC): A focus on age subgroups from EMPOWER-Lung 3

2026 · A. Baramidze, M. Gogishvili, et al. · ESMO Open

PDF

76P Impact of genomic alterations on clinical outcomes with first-line cemiplimab + chemotherapy for advanced NSCLC: An analysis from EMPOWER-Lung 3

2026 · V. Anagnostou, D.R. Gandara, et al. · ESMO Open

Cemiplimab plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer with PD-L1≥1%: 5‑year update of EMPOWER-Lung 3 results

2026 · P Hoffknecht, M Gogishvili, et al. · Pneumologie

92P The burden of delay: Diagnostic latency and tumor progression in soft tissue sarcomas — A real-world analysis from a developing country

2026 · M. Abuladze, E. Kekelia, et al. · ESMO rare cancers.

49P Baseline neutrophil-to-lymphocyte ratio as a predictive biomarker for immunotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis

2025 · N. Otkhozoria, E. Makharashvili, et al. · Immuno-Oncology Technology

125P Cemiplimab plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 results

2025 · M. Gogishvili, T. Makharadze, et al. · Immuno-Oncology Technology

236P Development and external validation of a predictive model for early severe immune-related adverse events in immune checkpoint inhibitor recipients, with deployment as a web-based calculator

2025 · D. Kvaratskhelia, N. Otkhozoria, et al. · Immuno-Oncology Technology

PDF

P1.11.52 Impact of Disease Progression on Pros in Patients Receiving Cemiplimab/Chemotherapy Versus Chemotherapy for aNSCLC: EMPOWER-Lung 3 Part 2

2025 · K. Penkov, A. Baramidze, et al. · Journal of Thoracic Oncology

P2.11A.26 Prognostic Utility of Peripheral Myeloid Cells for Clinical Outcomes in Patients with NSCLC Treated with Cemiplimab

2024 · R.J. Acosta, D.A.G. McIntyre, et al. · Journal of Thoracic Oncology

P4.11D.09 Fianlimab-Based Combination Therapies in Patients with Advanced Non-Small Cell Lung Cancer: Trials in Progress Updates

2024 · T. Melkadze, M. Gogishvili, et al. · Journal of Thoracic Oncology

PDF

1443P Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3

2023 · M. Gogishvili, T. Melkadze, et al. · Annals of Oncology

PDF

1495P Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results

2023 · A. Baramidze, T. Makharadze, et al. · Annals of Oncology

PDF

EP01.03-013 A Pilot Study of Lung Cancer Screening with Low Dose CT in Georgia (One Centre Experience and Preliminary Data)

2022 · S. Kukava, E. Mariamidze, et al. · Journal of Thoracic Oncology

Works count: 25

Citation count: 24

H-index: 3

I10-index: